JP2021527636A - Ｅａａｔ２活性化因子およびその使用方法 - Google Patents

Ｅａａｔ２活性化因子およびその使用方法 Download PDF

Info

Publication number
JP2021527636A
JP2021527636A JP2020567510A JP2020567510A JP2021527636A JP 2021527636 A JP2021527636 A JP 2021527636A JP 2020567510 A JP2020567510 A JP 2020567510A JP 2020567510 A JP2020567510 A JP 2020567510A JP 2021527636 A JP2021527636 A JP 2021527636A
Authority
JP
Japan
Prior art keywords
alkyl
membered
cycloalkyl
group
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527636A5 (https=
JPWO2019236625A5 (https=
Inventor
ケビン・ホジェッツ
チエン−リアン・グレン・リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2021527636A publication Critical patent/JP2021527636A/ja
Publication of JP2021527636A5 publication Critical patent/JP2021527636A5/ja
Publication of JPWO2019236625A5 publication Critical patent/JPWO2019236625A5/ja
Priority to JP2024133796A priority Critical patent/JP7794910B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020567510A 2018-06-04 2019-06-04 Ｅａａｔ２活性化因子およびその使用方法 Pending JP2021527636A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024133796A JP7794910B2 (ja) 2018-06-04 2024-08-09 Ｅａａｔ２活性化因子およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862680423P 2018-06-04 2018-06-04
US201862680418P 2018-06-04 2018-06-04
US62/680,423 2018-06-04
US62/680,418 2018-06-04
PCT/US2019/035452 WO2019236625A1 (en) 2018-06-04 2019-06-04 Eaat2 activators and methods of using thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024133796A Division JP7794910B2 (ja) 2018-06-04 2024-08-09 Ｅａａｔ２活性化因子およびその使用方法

Publications (3)

Publication Number Publication Date
JP2021527636A true JP2021527636A (ja) 2021-10-14
JP2021527636A5 JP2021527636A5 (https=) 2022-07-29
JPWO2019236625A5 JPWO2019236625A5 (https=) 2022-07-29

Family

ID=68771005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567510A Pending JP2021527636A (ja) 2018-06-04 2019-06-04 Ｅａａｔ２活性化因子およびその使用方法
JP2024133796A Active JP7794910B2 (ja) 2018-06-04 2024-08-09 Ｅａａｔ２活性化因子およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024133796A Active JP7794910B2 (ja) 2018-06-04 2024-08-09 Ｅａａｔ２活性化因子およびその使用方法

Country Status (9)

Country Link
US (3) US11702403B2 (https=)
EP (2) EP4685140A1 (https=)
JP (2) JP2021527636A (https=)
CN (1) CN112533601B (https=)
AU (1) AU2019282231B2 (https=)
CA (1) CA3102762A1 (https=)
ES (1) ES3041367T3 (https=)
IL (1) IL279199B1 (https=)
WO (1) WO2019236625A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3877376T3 (da) 2018-11-06 2023-10-02 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
CA3118908A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
AU2019374812B2 (en) 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
CN113939295B (zh) * 2019-03-20 2025-05-16 金翅雀生物公司 哒嗪酮及其使用方法
EP4149621B1 (en) * 2020-05-13 2024-10-30 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2016507539A (ja) * 2013-02-07 2016-03-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 大環状ピリダジノン誘導体
JP2016508505A (ja) * 2013-02-07 2016-03-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリダジノン−アミド誘導体
CN106467495A (zh) * 2015-08-19 2017-03-01 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及用途
WO2018081378A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260756A (en) * 1979-11-15 1981-04-07 American Cyanamid Company 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines
US4404203A (en) * 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
AU691673B2 (en) * 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
CA2742411A1 (en) * 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
AUPR606401A0 (en) * 2001-07-02 2001-07-26 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
JP2003313169A (ja) * 2002-04-19 2003-11-06 Otsuka Chemical Holdings Co Ltd ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2008219166B2 (en) * 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
US8426412B2 (en) 2008-04-08 2013-04-23 Dow Agrosciences, Llc. 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides
EP2196465A1 (en) * 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
US9447075B2 (en) * 2011-08-02 2016-09-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as EAAT2 activators
CN103664895B (zh) * 2012-08-28 2018-02-27 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及其用途
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
KR102420322B1 (ko) * 2014-06-17 2022-07-13 키에시 파르마슈티시 엣스. 피. 에이. 포스포이노시타이드 3-키나아제 억제제로서 인돌리진 유도체
WO2017123991A1 (en) 2016-01-15 2017-07-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2016507539A (ja) * 2013-02-07 2016-03-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 大環状ピリダジノン誘導体
JP2016508505A (ja) * 2013-02-07 2016-03-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリダジノン−アミド誘導体
CN106467495A (zh) * 2015-08-19 2017-03-01 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及用途
WO2018081378A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU, DONG ET AL.: "Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by I", ACS INFECTIOUS DISEASES, vol. 3(3),, JPN7023002260, 2017, pages 199 - 205, ISSN: 0005406469 *

Also Published As

Publication number Publication date
JP2024160326A (ja) 2024-11-13
US12286420B2 (en) 2025-04-29
US20210171497A1 (en) 2021-06-10
US20230138663A1 (en) 2023-05-04
ES3041367T3 (en) 2025-11-11
WO2019236625A1 (en) 2019-12-12
IL279199A (en) 2021-01-31
IL279199B1 (en) 2026-04-01
JP7794910B2 (ja) 2026-01-06
CN112533601A (zh) 2021-03-19
EP4685140A1 (en) 2026-01-28
AU2019282231A1 (en) 2021-01-14
US20240208936A1 (en) 2024-06-27
US11702403B2 (en) 2023-07-18
CN112533601B (zh) 2024-08-16
AU2019282231B2 (en) 2025-04-17
EP3801528A1 (en) 2021-04-14
EP3801528A4 (en) 2022-03-09
EP3801528B1 (en) 2025-08-06
CA3102762A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP7794910B2 (ja) Ｅａａｔ２活性化因子およびその使用方法
JP7590185B2 (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
AU2017393082B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN106146391A (zh) 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
US11377436B2 (en) EAAT2 enhancing molecules
AU2021200164A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP1611128A2 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
CA3031136A1 (en) Substituted imidazo[1,2-a]pyridin-3-yl compounds and their use for the treatment and/or prevention of respiratory disorders
JP6985271B2 (ja) アルキニルジヒドロキノリンスルホンアミド化合物
KR20140105598A (ko) [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도
JP2012514006A (ja) ３．１．０二環式ＧｌｙＴ１阻害剤ならびにその作製および使用の方法
JP6831376B2 (ja) トリアゾール誘導体
CN104955809A (zh) 取代的乙炔衍生物及其作为mGluR4的正变构调节剂的用途
JP2025511179A (ja) ピペラジンコア又は１，４－ジアゼパンコアを含むｔ型カルシウムチャネル調節因子及びその使用方法
TW202233578A (zh) Ｔ型鈣離子通道調節劑及其使用方法
HK40042691A (en) Eaat2 activators and methods of using thereof
HK40042691B (en) Eaat2 activators and methods of using thereof
CN114315689B (zh) 二硫烷基邻苯二甲酰亚胺类化合物、其制备方法和用途
TW201811761A (zh) 用於治療用途之化合物
CN119255802A (zh) 包含氮杂螺壬烷核的t型钙通道调节剂和其使用方法
JP2025511208A (ja) アザスピロヘプタンコアを含むｔ型カルシウムチャネル調節因子及びその使用方法
JP2025511207A (ja) ジアザスピロヘプタンコアを含むｔ型カルシウムチャネル調節因子及びその使用方法
CN119367357A (zh) Psph抑制剂在制备预防、治疗或改善神经系统疾病的药物中的用途
HK40097181A (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
HK40086209B (zh) 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903